Federal contract award
80JSC022PA009
IN-SPACE PRODUCTION OF STEM CELL THERAPIES
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | National Aeronautics and Space Administration |
| Office | NASA JOHNSON SPACE CENTER |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AR12 — SPACE R&D SERVICES; SPACE FLIGHT, RESEARCH AND SUPPORTING ACTIVITIES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $3.5M |
| Current contract value | $3.5M |
| Potential contract value / ceiling | $3.5M |
| Start date | Sep 21, 2022 |
| Current end date | Dec 30, 2026 |
| Potential end date | Dec 30, 2026 |
| Latest award activity | Sep 3, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 12 of 12 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 3, 2026 | P00011 | $599.9K | THE PURPOSE OF THIS MODIFICATION IS TO INCREASE INCREMENTAL FUNDING FROM $2,930,391 TO $3,530,300.06 AN INCREASE OF $599,909.06. |
| Jan 27, 2026 | P00010 | $900.0K | CEDARS-SINAI IS TO PERFORM ONE OR MORE PHASES OF THE INSPA PROGRAM TO DEVELOP, DEMONSTRATE AND MATURE SELECTED IN-SPACE MANUFACTURING OR PRODUCTION TECHNOLOGIES, LEADING TO SUCCESSFUL TRANSITION TO COMMERCIAL OPERATIONS ON A CLD. |
| Dec 3, 2025 | P00009 | $150.0K | IN-SPACE PRODUCTION OF STEM CELL THERAPIES |
| Sep 18, 2025 | P00008 | $145.0K | IN-SPACE PRODUCTION OF STEM CELL THERAPIES |
| Jul 30, 2024 | P00006 | $145.0K | IN-SPACE PRODUCTION OF STEM CELL THERAPIES |
| Jul 30, 2024 | P00007 | $0 | IN-SPACE PRODUCTION OF STEM CELL THERAPIES |
| Jul 16, 2024 | P00005 | $0 | IN-SPACE PRODUCTION OF STEM CELL THERAPIES |
| Dec 18, 2023 | P00004 | $290.0K | IN-SPACE PRODUCTION OF STEM CELL THERAPIES |
| Aug 11, 2023 | P00002 | $290.0K | IN-SPACE PRODUCTION OF STEM CELL THERAPIES |
| Aug 11, 2023 | P00003 | $0 | IN-SPACE PRODUCTION OF STEM CELL THERAPIES |
| Apr 18, 2023 | P00001 | $290.0K | IN-SPACE PRODUCTION OF STEM CELL THERAPIES |
| Sep 21, 2022 | 0 | $720.4K | IN-SPACE PRODUCTION OF STEM CELL THERAPIES |
Estimated positioning window
Oct 25, 2026 – Jan 23, 2027
80/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 80/100. Available recorded signals: 75 points.
- Contract end 2026-12-30 (66 days from calculation)
- +35 points
- 50 historical awards in this buyer and category group
- +15 points
- 12 recorded award transactions
- +10 points
- Latest award action: 2026-09-03
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.